Monday, August 05, 2013 5:00:10 PM
Leerink said the CMS ventricular assist device, or VAD, national coverage determination was largely in line with Street expectations and is an incremental positive for Thoratec (THOR) given the Bridge-to-Transplant vs. Destination Therapy destination remains intact. The firm said the proposal could be a perceived negative for HeartWare (HTWR) given some investors hoped for elimination of the designation.
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM